Grand View Research, Inc.の新刊レポートによると、世界の医療バイオミメテイックスの市場規模は2030年までに522億ドルに達し、予測期間中のCAGRは6.7％と予想されます。ナノテクノロジーの進歩の加速、プロテーゼやインプラントの需要の増加、医療バイオミメティックスに関連する研究開発活動の増加、および主要な市場プレーヤーによる戦略的事業活動などが、市場の主な成長要因です。たとえば、2021 年 4 月、curasan AG はヨーロッパでの流通ネットワークを拡大し、Silesia Dental および Implants Diffusion International SARLをヨーロッパの流通ネットワークに追加しました。
角膜に影響を与える疾患は、世界中の失明の最も重要な原因です。 WHO によると、毎年約 200 万件の角膜失明の新規症例が報告されています。世界中で 3,000 万人を超える人々が、角膜疾患やけがで片目または両目を失明しており、視力の低下に苦しんでいる人もいます。人工角膜の信頼性が高く、堅牢でスケーラブルなソリューションを作成するための多くの試みは成功していません。そのため、満たされていないニーズが存在し、病状、損傷、および角膜損傷失明に対する手頃な価格で長期的な解決策のために研究開発活動が行われています。たとえば、2022 年 3 月、LV プラサード眼科研究所、IIT ハイデラバード＆細胞、および分子生物学センターの研究者は、角膜失明の主な原因である角膜瘢痕の治療に使用できる、廃棄されたヒト角膜から製造された独自のバイオミメティック角膜ヒドロゲルを開発しました。
目次
Table of Contents
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Solutionology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Medical Biomimetics Market Variables, Trends, & Scope
4.1 Medical Biomimetics Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration and Growth Prospect Mapping
4.3 Market Driver Analysis
4.3.1 Growing Advancement In Nanotechnology
4.3.2 Increasing Demand For Prostheses And Implants
4.3.3 Rise In Research And Development Activities Associated With Medical Biomimetics
4.4 Market Restraint Analysis
4.4.1 Stringent Regulatory Framework
4.5 Key Opportunities
4.5.1 Growing Tissue Engineering Market
4.6 Medical Biomimetics Market - Pestle Analysis
4.7 Industry Analysis - Porter’s
4.8 Major Deals And Strategic Alliances Analysis
4.8.1 Joint Ventures
4.8.2 Mergers And Acquisitions
4.8.3 Licensing And Partnership
4.8.4 Technology Collaborations
4.8.5 Strategic Divestments
4.9 COVID-19 Impact Analysis
Chapter 5 Medical Biomimetics Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)
5.1 Global Medical Biomimetics Market: Product Movement Analysis
5.2 Cardiovascular
5.2.1 Cardiovascular Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.3 Orthopedic
5.3.1 Orthopedic Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.4 Ophthalmology
5.4.1 Ophthalmology Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.5 Dental
5.5.1 Dental Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.6 Others
5.6.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Medical Biomimetics Market- Segment Analysis, By Application, 2018 - 2030 (Usd Million)
6.1 Medical Biomimetics Market: Application Movement Analysis
6.2 Wound Healing
6.2.1 Wound Healing Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.3 Tissue Engineering
6.3.1 Tissue Engineering Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.4 Drug Delivery
6.4.1 Drug Delivery Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.5 Other Applications
6.5.1 Other Applications Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Medical Biomimetics Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)
7.1 Medical Biomimetics Market: Regional Movement Analysis
7.2 North America
7.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.2 U.K.
7.3.2.1 Uk Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.3 China
7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.4 India
7.4.4.1 India Market Estimates And Forecast, 2018-2030
7.4.5 South Korea
7.4.5.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4.6 Australia
7.4.6.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Market Estimates AND FORECAST, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6 Middle East & Africa (Mea)
7.6.1 Middle East & Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.6.4 Uae
7.6.4.1 Uae Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Public Companies
8.1.1 Company Market Position Analysis
8.1.2 Competitive Dashboard Analysis
8.1.3 Strategic Framework
8.2 Private Companies
8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
8.2.2 Regional Network Map
8.3 Company Profiles
8.3.1 OTSUKA MEDICAL DEVICES GROUP
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 STRYKER
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 ABBOTT
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 AVINENT SCIENCE AND TECHNOLOGY
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 SYNTOUCH INC
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 OSTEOPORE INTERNATIONAL PTE LTD
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 VANDSTROM, INC.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 BIOMIMETICS TECHNOLOGIES INC
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 SWEDISH BIOMIMETICS 3000 APS
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 LIFEMATRIX
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
8.3.11 KEYSTONE DENTAL GROUP
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives
8.3.12 CURASAN, INC.
8.3.12.1 Company Overview
8.3.12.2 Financial Performance
8.3.12.3 Product Benchmarking
8.3.12.4 Strategic Initiatives
8.3.13 CORNEAT VISION
8.3.13.1 Company Overview
8.3.13.2 Financial Performance
8.3.13.3 Product Benchmarking
8.3.13.4 Strategic Initiatives
8.3.14 NANOHIVE MEDICAL LLC
8.3.14.1 Company Overview
8.3.14.2 Financial Performance
8.3.14.3 Product Benchmarking
8.3.14.4 Strategic Initiatives
8.3.15 ZIMMER BIOMET
8.3.15.1 Company Overview
8.3.15.2 Financial Performance
8.3.15.3 Product Benchmarking
8.3.15.4 Strategic Initiatives
